Khan, Arif

Severity of Depression and Response to Antidepressants and Placebo: An Analysis of the Food and Drug Administration Database

Khan, A., Leventhal, R. M., Khan, S. R., & Brown, W. A. (2002) · Journal of Clinical Psychopharmacology

Treatment of Major DepressionPain Management and Placebo Effect

Cited by 456

The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Berman, R. M., Marcus, R. N., Swanink, R., McQuade, R. D., Carson, W. H., Corey-Lisle, P. K., & Khan, A. (2007) · The Journal of Clinical Psychiatry

Treatment of Major DepressionSchizophrenia research and treatment

Cited by 409

A systematic review of comparative efficacy of treatments and controls for depression

Khan, A., Faucett, J., Lichtenberg, P., Kirsch, I., & Brown, W. A. (2012) · PLoS ONE

Treatment of Major DepressionPsychotherapy Techniques and Applications

Cited by 288

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study

Sanacora, G., Johnson, M. R., Khan, A., Atkinson, S. D., Riesenberg, R. R., Schronen, J. P., Burke, M. A., Zajecka, J. M., Barra, L., Su, H.-L., et al. (2017) · Neuropsychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 120

Why Has the Antidepressant–Placebo Difference in Antidepressant Clinical Trials Diminished over the Past Three Decades?

Khan, A., Bhat, A., Kolts, R., Thase, M. E., & Brown, W. (2010) · CNS Neuroscience & Therapeutics

Treatment of Major DepressionPain Management and Placebo Effect

Cited by 78

Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial

Mathews, M., Gommoll, C., Chen, D., Nunez, R., & Khan, A. (2015) · International Clinical Psychopharmacology

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 77

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: A phase III, randomized, double-blind, fixed-dose, placebo-controlled study

Bakish, D., Bose, A., Gommoll, C., Chen, C., Nunez, R., Greenberg, W. M., Liebowitz, M., & Khan, A. (2014) · Journal of Psychiatry and Neuroscience

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 70

The conundrum of depression clinical trials: one size does not fit all

Khan, A., Mar, K. F., & Brown, W. A. (2018) · International Clinical Psychopharmacology

Treatment of Major DepressionStatistical Methods in Clinical Trials

Cited by 30

Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d

Khan, A., Musgnung, J., Ramey, T., Messig, M., Buckley, G., & Ninan, P. T. (2014) · Journal of Clinical Psychopharmacology

Treatment of Major DepressionMental Health Treatment and Access

Cited by 30

Analysis of Suicidality in Pooled Data From 2 Double-Blind, Placebo-Controlled Aripiprazole Adjunctive Therapy Trials in Major Depressive Disorder

Weisler, R. H., Khan, A., Trivedi, M. H., Yang, H., Eudicone, J. M., Pikalov, A., Tran, Q. V., Berman, R. M., & Carlson, B. X. (2011) · The Journal of Clinical Psychiatry

Treatment of Major DepressionSuicide and Self-Harm Studies

Cited by 19